Table 1. Factors previously reported to... | American Society of Hematology

Table 1.

Factors previously reported to be independently associated with increased risk of major bleeding in patients with cancer-associated VTE

Study	Clinical factor or biomarker	Estimated risk (95% CI)
Prandoni et al, 2002⁴	Genitourinary cancer*	HR: 4.5 (2.1-9.9)†
	Extensive cancer	HR: 4.8 (2.3-10.1)†
Trujillo-Santos et al, 2008⁵	Metastatic cancer	OR: 1.6 (1.1-2.3)
	Immobility ≥ 4 d	OR: 1.8 (1.2-2.7)
	Creatinine clearance < 30 mL/min	OR: 2.2 (1.5-3.4)
	Recent major bleeding	OR: 2.4 (1.1-5.1)
Kamphuisen et al, 2015¹⁵	Metastatic cancer	RR: 1.6 (1.1-2.3)
	Intracranial lesion	RR: 2.0 (1.1-3.5)
	Age > 75 y	RR: 1.8 (1.2-2.7)
Mahé et al, 2017¹¹‡	Lung cancer	HR: 1.8 (1.1-3.0)‡
	Colorectal cancer	HR 2.1 (1.3-3.4)‡
	Prostate cancer	HR: 2.1 (1.3-3.5)‡
	Cancer diagnosis within past 3 mo	HR: 1.6 (1.1-2.3)
	Platelet count < 100 × 10⁹/L	HR: 2.0 (1.4-3.0)
	Recent major bleeding	HR: 5.0 (3.1-7.9)

Study	Clinical factor or biomarker	Estimated risk (95% CI)
Prandoni et al, 2002⁴	Genitourinary cancer*	HR: 4.5 (2.1-9.9)†
	Extensive cancer	HR: 4.8 (2.3-10.1)†
Trujillo-Santos et al, 2008⁵	Metastatic cancer	OR: 1.6 (1.1-2.3)
	Immobility ≥ 4 d	OR: 1.8 (1.2-2.7)
	Creatinine clearance < 30 mL/min	OR: 2.2 (1.5-3.4)
	Recent major bleeding	OR: 2.4 (1.1-5.1)
Kamphuisen et al, 2015¹⁵	Metastatic cancer	RR: 1.6 (1.1-2.3)
	Intracranial lesion	RR: 2.0 (1.1-3.5)
	Age > 75 y	RR: 1.8 (1.2-2.7)
Mahé et al, 2017¹¹‡	Lung cancer	HR: 1.8 (1.1-3.0)‡
	Colorectal cancer	HR 2.1 (1.3-3.4)‡
	Prostate cancer	HR: 2.1 (1.3-3.5)‡
	Cancer diagnosis within past 3 mo	HR: 1.6 (1.1-2.3)
	Platelet count < 100 × 10⁹/L	HR: 2.0 (1.4-3.0)
	Recent major bleeding	HR: 5.0 (3.1-7.9)

HR, hazard ratio; OR, odds ratio; RR, relative risk.

Uterus, kidney, ovary or testicle, bladder, and prostate.

Compared with patients without cancer.

Study included only patients with breast, prostate, colorectal, or lung cancer. Risk is relative to patients with breast cancer.